Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Recurrent High-grade Glioma
NCT03295396Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Oct 2017
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in glioma, sponsored by Chimerix Inc.. Started Oct 2017; status: terminated.
02
Drugs
dordaviprone
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03295396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295396.